TY - JOUR
T1 - Prevalence of infectious diseases in preterm infants
T2 - a 2-year follow-up from the Japan Environment and Children’s Study
AU - The Japan Environment and Children’s Study (JECS) Group
AU - Tamura, Kentaro
AU - Matsumura, Kenta
AU - Tsuchida, Akiko
AU - Yoshida, Taketoshi
AU - Inadera, Hidekuni
AU - Kamijima, Michihiro
AU - Yamazakii, Shin
AU - Ohya, Yukihiro
AU - Kishi, Reiko
AU - Yaegashi, Nobuo
AU - Hashimoto, Koichi
AU - Mori, Chisato
AU - Ito, Shuichi
AU - Yamagata, Zentaro
AU - Nakayama, Takeo
AU - Sobue, Tomotaka
AU - Shima, Masayuki
AU - Nakamura, Hiroshige
AU - Suganuma, Narufumi
AU - Kusuhara, Koichi
AU - Katoh, Takahiko
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Evidence regarding the long-term risk of infections in preterm infants is lacking. In this study, we examined whether preterm infants developed various common childhood infections more frequently than full-term infants by the age of 2 years by analyzing data from a questionnaire completed by 67,282 mother–toddler pairs in a nationwide birth cohort study. Of the target population, 2885 (4.3%) were born prematurely. After covariate adjustment for maternal and children factors, lower respiratory tract infections appeared more frequent in preterm than in full-term infants at both 1 and 2 years (adjusted odds ratio [aOR] 1.21, 95% confidence interval [CI] 1.05–1.41, and aOR 1.27, 95% CI 1.11–1.46, respectively). However, there was no significant difference in the frequencies of lower respiratory tract infection between preterm and full-term infants after Palivizumab administration. The risk of other common infections, such as in the upper respiratory tract infection, otitis media, urinary tract infection, gastroenteritis, herpangina, hand-foot-and-mouth disease, chickenpox, influenza virus, and adenovirus infections, was not higher in preterm than in full-term infants after covariates adjustment for maternal and children factors. These findings suggest Palivizumab prophylaxis could reduce the frequencies of lower respiratory tract infection in preterm to the same level as in full-term infants.
AB - Evidence regarding the long-term risk of infections in preterm infants is lacking. In this study, we examined whether preterm infants developed various common childhood infections more frequently than full-term infants by the age of 2 years by analyzing data from a questionnaire completed by 67,282 mother–toddler pairs in a nationwide birth cohort study. Of the target population, 2885 (4.3%) were born prematurely. After covariate adjustment for maternal and children factors, lower respiratory tract infections appeared more frequent in preterm than in full-term infants at both 1 and 2 years (adjusted odds ratio [aOR] 1.21, 95% confidence interval [CI] 1.05–1.41, and aOR 1.27, 95% CI 1.11–1.46, respectively). However, there was no significant difference in the frequencies of lower respiratory tract infection between preterm and full-term infants after Palivizumab administration. The risk of other common infections, such as in the upper respiratory tract infection, otitis media, urinary tract infection, gastroenteritis, herpangina, hand-foot-and-mouth disease, chickenpox, influenza virus, and adenovirus infections, was not higher in preterm than in full-term infants after covariates adjustment for maternal and children factors. These findings suggest Palivizumab prophylaxis could reduce the frequencies of lower respiratory tract infection in preterm to the same level as in full-term infants.
UR - http://www.scopus.com/inward/record.url?scp=85145090248&partnerID=8YFLogxK
U2 - 10.1038/s41598-022-26748-0
DO - 10.1038/s41598-022-26748-0
M3 - 学術論文
C2 - 36577762
AN - SCOPUS:85145090248
SN - 2045-2322
VL - 12
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 22488
ER -